Your browser doesn't support javascript.
loading
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine, Marie; Mauric, Eleonora; Tison, Alice; Barnetche, Thomas; Barre, Aurélien; Nikolski, Macha; Rouxel, Léa; Dutriaux, Caroline; Dousset, Léa; Prey, Sorilla; Beylot-Barry, Marie; Seneschal, Julien; Veillon, Rémi; Vergnenegre, Charlotte; Daste, Amaury; Domblides, Charlotte; Sionneau, Baptiste; Gross-Goupil, Marine; Ravaud, Alain; Forcade, Edouard; Schaeverbeke, Thierry.
Afiliación
  • Kostine M; Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France. Electronic address: marie.kostine@chu-bordeaux.fr.
  • Mauric E; Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.
  • Tison A; Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.
  • Barnetche T; Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.
  • Barre A; Bordeaux Bioinformatics Center (CBiB), Bordeaux, France.
  • Nikolski M; Bordeaux Bioinformatics Center (CBiB), Bordeaux, France.
  • Rouxel L; Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.
  • Dutriaux C; Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.
  • Dousset L; Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.
  • Prey S; Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.
  • Beylot-Barry M; Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.
  • Seneschal J; Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.
  • Veillon R; Department of Pulmonology, Bordeaux University Hospital, Bordeaux, France.
  • Vergnenegre C; Department of Pulmonology, Bordeaux University Hospital, Bordeaux, France.
  • Daste A; Department of Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Domblides C; Department of Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Sionneau B; Department of Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Gross-Goupil M; Department of Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Ravaud A; Department of Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Forcade E; Department of Hematology, Bordeaux University Hospital, Bordeaux, France.
  • Schaeverbeke T; Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.
Eur J Cancer ; 157: 474-484, 2021 11.
Article en En | MEDLINE | ID: mdl-34649118
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos bajo Prescripción / Microbioma Gastrointestinal / Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos bajo Prescripción / Microbioma Gastrointestinal / Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido